A Safety Monitoring Procedure for a Clinical Drug Development Program, with Application to the Assessment of a Novel COX-2 Inhibitor

Author： Bolland Kim  

Publisher： Taylor & Francis Ltd

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.18, Iss.4, 2008-07, pp. : 737-749

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical pharmacology of etoricoxib: a novel selectiveCOX2 inhibitor

By Patrignani Paola   Capone Marta L   Tacconelli Stefania  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 2, 2003-02 ,pp. : 265-284

Informa Healthcare

Access to resources Recommend Favorite

The clinical developments and future of the COX-2 inhibitor drugs

By Goldstein Jerome  

Inflammopharmacology, Vol. 9, Iss. 1-2, 2001-05 ,pp. : 91-99

VSP

Access to resources Recommend Favorite

Clinical pharmacology of celecoxib, a COX-2 selective inhibitor

By Antoniou Katerina   Malamas Michael   Drosos Alexandros A  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 11, 2007-08 ,pp. : 1719-1732

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacology of Novel Selective COX-2 Inhibitors

By  

Current Pharmaceutical Design, Vol. 10, Iss. 6, 2004-02 ,pp. : 589-601

Bentham Science Publishers

Access to resources Recommend Favorite

GCG100649, A Novel Cyclooxygenase‐2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase‐I/II: Preliminary Dose–Exposure Relationships to Define Clinical Development Strategies

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 379-386

John Wiley & Sons Inc

Access to resources Recommend Favorite